Ticker brief · 2026-06-22
TGTX TG THERAPEUTICS INC
Momentum bulls dominate as biotech flows reinforce TGTX breakout
Consumer, Non-cyclical · Biotechnology
Lean: bullishlast close
$53.31
1 day
-0.4%
14 days
+0.2%
mkt cap
$8.2B
signals 14d
26
authors 14d
17
The tape is bullish, with credible voices focused on technical strength, Briumvi share gains, and a constructive biotech backdrop. The late-week shift was from simple breakout commentary into positioning confirmation through call activity, short-covering references, and sector accumulation signals. Trade structure looks momentum-led rather than fundamentally settled, with takeover talk mostly lower-credibility and better treated as optionality than base case.
BULL CAMP
Bulls argue TGTX has broken into a stronger technical regime while biotech flows, Briumvi share momentum, and pipeline optionality support continued re-rating. The highest-quality support is concentrated in market-share and chart/sector strength rather than takeover speculation.
Key voices@BiomavenMEDIUM-HIGHA+1.72@ThePupOfWallStMEDIUM-HIGHC-2.68@IBDinvestorsHIGHB+1.52@Venu_7_MEDIUM-HIGHB-0.45@MartyCharginMEDIUM-HIGHC-0.72
“Briumvi is approaching 50% dynamic share, supporting the fundamental growth case.”— @Biomaven · tweet ↗
BEAR / SKEPTIC
—
Hypotheses7direction · basis · magnitude · supporters — NEW = first seen this week
▲TGTX breakout above long-term resistance and continued relative strength put higher technical targets in play.
@ThePupOfWallStMEDIUM-HIGHC-2.681s@IBDinvestorsHIGHB+1.521s@HiddenPivotsMEDIUMC+0.981s@MartyCharginMEDIUM-HIGHC-0.722s@zohmbasticMEDIUMC-1.001s@2000STOCKMASTERLOWC-4.192s
▲Biotech and XBI accumulation create a supportive sector tape for TGTX and related growth biotech names.
@Venu_7_MEDIUM-HIGHB-0.451s · insight@spluscollectiveMEDIUMC-2.801s@PrismMarketViewMEDIUM-HIGHC1s@RealHeel80MEDIUMC+0.531s@RoyLMattoxMEDIUM-HIGHC-1.341s@semodoughMEDIUM-HIGHC-0.751s
▲Briumvi nearing 50% dynamic market share validates TGTX commercial execution and supports fundamental upside.
@BiomavenMEDIUM-HIGHA+1.721s · insight
▲The Phase 1 allogeneic CAR-T autoimmune trial adds pipeline optionality beyond the core Briumvi story.
@BiomavenMEDIUM-HIGHA+1.721s · insight
◆A takeover or buyout could re-rate TGTX sharply, but the claim is promotion-heavy and weakly evidenced.
@2000STOCKMASTERLOWC-4.194s@YYDSxjmLOW-MEDIUMB+0.191s
▲Short covering and call buying can extend the move through positioning pressure rather than fundamentals alone.
@MartyCharginMEDIUM-HIGHC-0.721s@2000STOCKMASTERLOWC-4.191s@FlowbyBobbyLOW-MEDIUMC1s@JonEtradesLOW-MEDIUMC-1.721s
▲IBD rank inclusion and growth-screen attention may draw incremental momentum buyers into TGTX.
@fj_nextstageLOW-MEDIUMC+1.071s@IBDinvestorsHIGHB+1.521s
Direct calls1authors taking explicit directional positions
@RoyLMattoxMEDIUM-HIGHC-1.34
Added GH and XBI while flagging several biotech stocks as attractive, implying a constructive biotech basket stance.
Sellside activity1
Goldman noteGoldman listed healthcare conference names it left most incrementally positive on.
News / data points5discrete events + data quoted by authors
@semodoughMEDIUM-HIGHC-0.75
Goldman came away incrementally positive on selected healthcare conference names.
@BiomavenMEDIUM-HIGHA+1.72
Briumvi is nearing 50% dynamic market share.
@ThePupOfWallStMEDIUM-HIGHC-2.68
TGTX cleared long-term resistance, opening higher technical targets.
@FlowbyBobbyLOW-MEDIUMC
TGTX saw notable July 60 call buying.
@IBDinvestorsHIGHB+1.52
TGTX is up roughly 70% and still climbing.
Position disclosures1skin in the game
@YYDSxjmLOW-MEDIUMB+0.19
Long-term TGTX holder, not selling until buyout or $200.
Desk readconvergence assessment
Views are strongly converged on bullish price action and sector support, with no explicit bear camp in the payload. The credibility asymmetry is within the bull camp: Biomaven, IBDinvestors, Venu_7_, and ThePupOfWallSt carry the higher-quality evidence, while takeover speculation is concentrated in low-credibility promotion. The view would weaken if Briumvi share momentum stalls or the breakout fails after the recent call-buying and short-covering setup.
Tracked hypotheses — caliber-scored view · 2026-06-22
🟢 HIGH caliber (1)
📈 h2 bull · score 0.67
Biotech and XBI accumulation create a supportive sector tape for TGTX and related growth biotech names.
- Supporters (5): @Venu7(MEDIUM-,1p), @spluscollective↗(MEDIUM,1p), @RealHeel80↗(MEDIUM,1p), @RoyLMattox↗(MEDIUM-,1p), @semodough↗(MEDIUM-,1p)
- Signals: 6 · Max author share: 0.20 · Novelty: building
- Quote: "Biotech ETF is in a Stage 2 uptrend with accumulation." — Venu7
🟡 MEDIUM caliber (1)
📈 h1 bull · score 0.39
TGTX breakout above long-term resistance and continued relative strength put higher technical targets in play.
- Supporters (5): @ThePupOfWallSt↗(MEDIUM-,1p), @HiddenPivots↗(MEDIUM,1p), @MartyChargin↗(MEDIUM-,2p), @zohmbastic↗(MEDIUM,1p), @2000STOCKMASTER↗(LOW,2p)
- Signals: 8 · Max author share: 0.29 · Novelty: building
- Quote: "Long-term resistance cleared, with the next upside levels near 55 and 60." — ThePupOfWallSt
⚪ LOW caliber (1)
📈 h6 bull · score 0.23
Short covering and call buying can extend the move through positioning pressure rather than fundamentals alone.
- Supporters (4): @MartyChargin↗(MEDIUM-,1p), @2000STOCKMASTER↗(LOW,1p), @FlowbyBobby↗(LOW-MED,1p), @JonEtrades↗(LOW-MED,1p)
- Signals: 4 · Max author share: 0.25 · Novelty: building
- Quote: "July 60 call buying showed notable upside options demand." — FlowbyBobby
🔴 FLAGGED caliber (4)
📈 h3 bull · score 0.07
Briumvi nearing 50% dynamic market share validates TGTX commercial execution and supports fundamental upside.
- Supporters (1): @Biomaven↗(MEDIUM-,1p)
- Signals: 1 · Max author share: 1.00 · Novelty: stable
- ⚠️ Concentration: 100% from @biomaven↗ MEDIUM-HIGH cred
- Quote: "Briumvi is nearing 50% dynamic market share." — Biomaven
📈 h4 bull · score 0.07
The Phase 1 allogeneic CAR-T autoimmune trial adds pipeline optionality beyond the core Briumvi story.
- Supporters (1): @Biomaven↗(MEDIUM-,1p)
- Signals: 1 · Max author share: 1.00 · Novelty: stable
- ⚠️ Concentration: 100% from @biomaven↗ MEDIUM-HIGH cred
- Quote: "TGTX has a Phase 1 allogeneic CAR-T program in B-cell autoimmune disease." — Biomaven
⚠️ h5 flag · score 0.02
A takeover or buyout could re-rate TGTX sharply, but the claim is promotion-heavy and weakly evidenced.
- Supporters (2): @2000STOCKMASTER↗(LOW,4p), @YYDSxjm↗(LOW-MED,1p)
- Signals: 5 · Max author share: 0.80 · Novelty: stable
- ⚠️ Concentration: 80% from @2000stockmaster↗ LOW cred
- Quote: "Buyout speculation is framed as imminent after the stock strength." — 2000STOCKMASTER
📈 h7 bull · score 0.01
IBD rank inclusion and growth-screen attention may draw incremental momentum buyers into TGTX.
- Supporters (1): @fj_nextstage↗(LOW-MED,1p)
- Signals: 2 · Max author share: 1.00 · Novelty: stable
- ⚠️ Concentration: 50% from @fj_nextstage↗ LOW-MEDIUM cred
- Quote: "IBD50 rank changes were highlighted with chart context." — fj_nextstage
Sentiment — last 14 days
daily mean sentiment, 2026-06-21 → 2026-07-02 · now +0.00 (−1 bearish … +1 bullish)
Who spoke17
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @semodough | C | -0.75 | 4 | +0.52 |
| @2000STOCKMASTER | C | -4.19 | 3 | +0.27 |
| @Venu_7_ | B | -0.45 | 2 | +0.44 |
| @spluscollective | C | -2.80 | 2 | +0.45 |
| @YYDSxjm | B | +0.19 | 2 | +0.57 |
| @BoxTraderVK | C | +1.53 | 2 | +0.15 |
| @equitydd | C | +0.19 | 1 | +0.45 |
| @PK_Fund | C | +0.19 | 1 | +0.35 |
| @Omnitrader69 | C | -1.20 | 1 | +0.35 |
| @Biomaven | A | +1.72 | 1 | +0.75 |
| @fj_nextstage | C | +1.07 | 1 | +0.10 |
| @AlexMarenco1 | C | +0.75 | 1 | +0.00 |
| @BiopharmIQ | B | · | 1 | +0.25 |
| @BrandonVanZee | C | +0.63 | 1 | +0.35 |
| @capestrategico | C | -0.26 | 1 | +0.00 |
| @fundmyfund | B | -2.01 | 1 | +0.35 |
| @kkernttb | C | +1.42 | 1 | +0.00 |
Recent signals26of 26 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-07-02 | @2000STOCKMASTER | +0.00 | Watchlist-style tweet says everyone should look at VKTX with broad ticker list and no entry intent. | — | tweet ↗ |
| 2026-07-01 | @kkernttb | +0.00 | Updated watchlist with multiple tickers but no stance beyond watchlist. | -0.4% | tweet ↗ |
| 2026-06-30 | @fundmyfund | +0.35 | Says TGTX looks to be setting up with chart attached. | -3.0% | tweet ↗ |
| 2026-06-30 | @capestrategico | +0.00 | Weekly chart mention for TGTX without explicit stance. | -3.0% | tweet ↗ |
| 2026-06-29 | @YYDSxjm | +0.50 | Discloses 8-year investment and wants a buyout at $80-$120. | -4.3% | tweet ↗ |
| 2026-06-28 | @Venu_7_ | +0.62 | Positive view on breakout from long base with revenue and EPS growth. | -4.5% | tweet ↗ |
| 2026-06-28 | @BrandonVanZee | +0.35 | Says many health care charts look glorious and lists tickers. | -4.5% | tweet ↗ |
| 2026-06-27 | @spluscollective | +0.65 | TGTX and RVMD called favorite XBI names with monster bases; PT 70. | -4.5% | tweet ↗ |
| 2026-06-27 | @BiopharmIQ | +0.25 | Weekly biotech recap with multiple discrete company updates and sector themes, capped to first six tickers. | -4.5% | tweet ↗ |
| 2026-06-26 | @AlexMarenco1 | +0.00 | Market recap says chips led down, distribution days rose, and lists names of note. | -4.5% | tweet ↗ |
| 2026-06-26 | @fj_nextstage | +0.10 | IBD50 rank-up and rank-down data with 30-week charts. | -4.5% | tweet ↗ |
| 2026-06-26 | @BoxTraderVK | +0.10 | Meta commentary on focusing on setups, with tickers listed but no specific call. | -4.5% | tweet ↗ |
| 2026-06-26 | @semodough | +0.35 | Surprised short interest is high after SubQ disclosures that author says basically double TGTX current market. | -4.5% | tweet ↗ |
| 2026-06-25 | @BoxTraderVK | +0.20 | Focus list with setup criteria near MA, range, sector, catalyst, and volume. | -0.6% | tweet ↗ |
| 2026-06-25 | @YYDSxjm | +0.65 | Compares TGTX opportunity to Immunomedics revenue and peak sales. | -0.6% | tweet ↗ |
| 2026-06-24 | @2000STOCKMASTER | +0.35 | Calls listed names a right trading setup, but no specific entry or levels. | -0.5% | tweet ↗ |
| 2026-06-23 | @spluscollective | +0.25 | Calls INDV probably the best setup among XBI names while TGTX and RVMD are above buy zone. | -1.2% | tweet ↗ |
| 2026-06-22 | @semodough | +0.55 | Jefferies says SC formulation patents could extend exclusivity to 2045 and drive higher sales projections. | -2.0% | tweet ↗ |
| 2026-06-22 | @Biomaven | +0.75 | Author says TGTX subQ Briumvi case remains strong and calls it an easy buy and hold. | -2.0% | tweet ↗ |
| 2026-06-22 | @semodough | +0.65 | Jefferies sees TGTX free cash flow growing from $1B to over $3B over the next 10 years. | -2.0% | tweet ↗ |
| 2026-06-22 | @semodough | +0.55 | Jefferies raises TGTX PT to $83 from $57 on high confidence into Phase 3 subq CD20 RMS data. | -2.0% | tweet ↗ |
| 2026-06-22 | @Omnitrader69 | +0.35 | Reports levels touched and says killer day for larger plays. | -2.0% | tweet ↗ |
| 2026-06-22 | @PK_Fund | +0.35 | Reports one-patient trial improvement metrics from article. | -2.0% | tweet ↗ |
| 2026-06-21 | @equitydd | +0.45 | Highlights biotech stocks with strong price performance and positive net income. | +0.2% | tweet ↗ |
| 2026-06-21 | @Venu_7_ | +0.25 | Biotech ETF described as Stage 2 uptrend with accumulation and constructive sector setup. | +0.2% | tweet ↗ |
| 2026-06-21 | @2000STOCKMASTER | +0.45 | Names potential takeover picks in biotech names. | +0.2% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.